Enliven Therapeutics Inc

News & Events zu Enliven Therapeutics Inc (ELVN)

$57.860

-2.523 (-4.36%)Zum Schluss

ELVN-News

ELVN-Events

8/5 16:30

Enliven Cash and Securities Reach $895.2M, Preparing to Advance ELVN-001

As of June 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $895.2M, which is expected to provide cash runway into 2030. "Q2 was an important period for Enliven as we announced compelling updated clinical data for ELVN-001, reached alignment with the FDA on key components of the ENABLE-2 Phase 3 2L+ trial design, and significantly strengthened our balance sheet," said CEO Rick Fair. "The updated Phase 1 data support ELVN-001's potential to become a best-in-class treatment for patients living with CML. Combined with our recent regulatory and financial progress, we are well positioned to initiate ENABLE-2 later this year and rapidly advance ELVN-001 across all lines of CML therapy."

6/12 12:30

Enliven Stock Rises 9.9% to $44.37

Enliven is up 9.9%, or $4.01 to $44.37.

6/12 07:30

Deal Size Increased to $400M

The deal size was increased to $400M in common stock from $250M in common stock. Jefferies, Goldman Sachs, Morgan Stanley and Barclays acted as joint book running managers for the offering.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten